2 Information about dapagliflozin
Marketing authorisation indication
2.1 Dapagliflozin (Forxiga, AstraZeneca) is indicated in adults for 'the treatment of symptomatic chronic heart failure'.
2.2 Dapagliflozin is recommended for treating chronic heart failure with reduced ejection fraction in adults (NICE technology appraisal guidance 679).
Dosage in the marketing authorisation
2.3 The dosage schedule is available in the summary of product characteristics for dapagliflozin.